by nms-sync | Jan 10, 2023 | News
NEWS
MPS1 Kinase Inhibitor Shows Clinical Activity in Primary Liver Cancer
The targeted drug NMS-01940153E, a monopolar spindle 1 (MPS1) kinase inhibitor, has shown signs of clinical activity in a Phase I study of patients with relapsed or...
by nms-sync | Jan 10, 2023 | News
Nerviano, 9 January 2023 NMS Group S.p.A. (NMS Group), the largest oncological R&D company in Italy, announces the appointment of Ms. Sidney Dung as Chief Operating Officer with immediate effect. Ms. Dung, currently a member of the Company’s Executive Leadership...
by nms-sync | Nov 4, 2022 | News
A week from the presentation of Nerviano Medical Sciences S.r.l. (a member of NMS Group) on NMS-01940153E (NMS-153) at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, we’re thrilled to share the official press release from ENA 2022 of...
by nms-sync | Oct 28, 2022 | News
Nerviano Medical Sciences S.r.l. Shared Data on NMS-01940153E selected for Oral Presentation at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
NERVIANO, 28 October 2022 – Nerviano Medical Sciences Srl (Company), a member of NMS...
by nms-sync | Oct 26, 2022 | News
NERVIANO, 25 October 2022 – Nerviano Medical Sciences Srl, a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that preclinical data from the Company’s asset NMS-03602173 will...
Welcome and Check out our new motion picture!
Recent Comments